Drugs / DanshenDuofensuanyan
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02870764 Comparator | Sep 2016 → May 2017 | intermediate coronary syndrome | Taizhou Fourth People's Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DanshenDuofensuanyan | “Participants will then undergo treatment with DanshenDuofensuanyan injection or placebo (glucose) during hospitalization, followed by open-label Danshen drop spill (30...” PMID 29262859 ↗ Dec 2017 |
| Known as | DanshenDuofensuanyan injection | “A total of 156 patients meeting the eligibility criteria will be randomly assigned to either the Danshen extract (DanshenDuofensuanyan injection and Danshen drop spill) group...” PMID 29262859 ↗ Dec 2017 |
| Modality | Traditional medicine (herbal / TCM) | “To date, very few studies have examined the Chinese herbal drug Danshen or its extract on Lp-PLA2 in patients with stable angina pectoris.” PMID 29262859 ↗ Dec 2017 |
| Route | Intravenous | “given by continuous IV infusion at 2.5ml/min within 2 hours” NCT02870764 ↗ |